Merck and Moderna’s Intismeran Autogene Plus Keytruda Meets Phase 3 RFS and DMFS Endpoints in Resected Melanoma
oncodaily - Merck and Moderna announced positive topline results from the Phase 3 INTerpath-001 trial, evaluating intismeran autogene (V940/mRNA-4157) plus Keytruda (pembrolizumab) as adjuvant treatment for patients with completely resected stage IIB-IV […]
AI Summary: Merck and Moderna announced that their mRNA-based melanoma vaccine, given with Keytruda, met key phase‑3 endpoints — reducing recurrence and distant metastasis after resection. The data suggest the vaccine can prime anti‑tumor immunity to prevent relapse, positioning it as a potential adjunct to standard checkpoint inhibition in high‑risk patients.
- Experts weigh in on personalized mRNA cancer vaccines (4)
- INTerpath-001: phase‑3 vaccine reduces melanoma recurrence (6)
- Market surge: Moderna's stock jumps after trial news (3)
- All Other Stories
Experts weigh in on personalized mRNA cancer vaccines
INTerpath-001: phase‑3 vaccine reduces melanoma recurrence
Market surge: Moderna's stock jumps after trial news
All Other Stories
Related Stories
Belzutifan plus lenvatinib outperforms cabozantinib in advanced RCC / 11 days
First patient enrolled in AACR-ADOPT-GEA gastroesophageal cancer trial / 22 days
Phase 1 trial shows cevostamab activity in relapsed multiple myeloma / 5 wks
EMERALD‑3 tests tremelimumab/durvalumab combos for embolisation‑eligible HCC / 1 month
Long‑term Botensilimab+Balstilimab data show durable responses in MSS CRC / 2 months
Zanidatamab improves PFS over trastuzumab in HER2 GEA / 2 months
MAGE‑A4/A8 TCR bispecific T‑cell engager shows activity in solid tumors / 2 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Oncology, Adolescent Health, Medicare Advantage (not listed), Pharmaceuticals and look for the RSS link.
StackHealth Time Machine